Universitat De Les Illes Balears

Other

Universidad De Les Illes Balears

Devicare Sl

Félix Grases Freixedas

Joan Perello Bestard

Antonia Costa Bauza

Rafael M Prieto Almirall

Antonia Costa Bauzá

Adrián Rodríguez Rodríguez

Rafael María Prieto Almirall

Fernando Tur Espinosa

Isabel Gomila Muñiz

Bernat Isern Amengual

Pilar Sanchis Cortes

Joan Perelló Bestard

Sebastián Albertí Serrano

Jordi CuÑÉ Castellana

Adrian RODRÍGUEZ RODRÍGUEZ

Antonia Costa BauzÀ

Rafael Mará Prieto Almirall

Ramón GARCÍA GONZÁLEZ

Adrían RODRÍGUEZ RODRÍGUEZ

Pilar Sanchís Cortés

Antonia Costa-bauzá

Paula Calvó García

Margalida Mateu Borrás

The present invention is related to a composition comprising phytic acid or a phytate salt, magnesium in the form of salt, hydroxide or oxide and optionally at least one polyphenol. These components may be in isolated form or be part of an enriched plant extract. The invention is also related to the use of this composition for the treatment of renal lithiasis, preferably calcium or calcium oxalate lithiasis, either in the form of a medicament, a nutraceutical or functional food or food supplement.

Composition containing phytic acid, magnesium and polyphenols for the treatment or prevention of renal lithiasis

The present invention is related to the use of a separate, sequential or simultaneous combination of at least one urinary acidifier with at least one calcium phosphate crystallization inhibitor for urine acidification, and thus preventing the pH at which supersaturation of calcium phosphate is produced and consequently, renal lithiasis.

Combined preparations of urinary acidifiers and crystallization inhibitors and application thereof for the treatment or prevention of phosphatic or calcium phosphate-induced renal lithiasis

The present invention refers to the use of theobromine or its derivatives as an inhibitor of the crystallization of uric acid to avoid the formation of uric acid crystals in urine and as a consequence renal lithiasis or specifically uric acid renal lithiasis.

Theobromine or its derivatives for the treatment or prevention of renal lithiasis

This invention relates to a composition that comprises inositol phosphates and/or bisphosphonates, and to the use thereof to prevent the loss of substances of biological interest in the body of patients subjected to dialysis and to maintain sufficient physiological levels of said substances to regulate physiological and/or pathological processes, these substances being inhibitors of pathological crystallization.

Composition of dialysis liquid comprising crystallisation inhibitor substances

The invention relates to a fixed-dose association of 5 phytate and zinc in synergic proportions for use in the treatment of crystallization of hydroxyapatite. Advantageously, said association is in a molar ratio between the phytate and the zinc exceeding 4:1. The invention also relates to the use of said 10 association for manufacturing a drug for the treatment, prophylaxis and/or prevention crystallization of hydroxyapatite in humans.

Fixed-dose association of phytate and zinc

Growing community of inventors

Palma De Mallorca, Spain

Félix Grases Freixedas